Video yükleniyor...

Video Yüklenemedi

Ana Sayfaya Dön

We are thrilled to share positive topline data from our ELEVATE IPF Phase 2b trial evaluating deupirfenidone (LYT-100) for the treatment of idiopathic pulmonary fibrosis (#IPF), a progressive and fatal lung disease. Our trial met the primary and key secondary endpoints, with deupirfenidone demonstrating the potential to serve as...

PureTechH's profile picture

PureTech

4,263 subscribers

10,892 görüntüleme • 1 yıl önce •via X (Twitter)

Sağlık & İyilikBilim & TeknolojiHaberler & Politika#IPF
LIVE

Anya Rossi• Live Now

Private livecam show

1 Yorum

jingscrivens profil fotoğrafı
jingscrivens1 yıl önce

Great of luck for 2025

Benzer Videolar

Today, we announced the completion of enrollment in our global BROADEN2 Phase 2b trial of KT-621, our investigational, first-in-class, oral STAT6 degrader, in atopic dermatitis, nearly six months ahead of anticipated timelines. This milestone enables us to accelerate our expected topline data readout to year-end 2026 and continue advancing KT-621 as a potential oral treatment option for patients living with atopic dermatitis and other Type 2 inflammatory diseases. Read more in our press release:
0:45

Today, we announced the completion of enrollment in our global BROADEN2 Phase 2b trial of KT-621, our investigational, first-in-class, oral STAT6 degrader, in atopic dermatitis, nearly six months ahead of anticipated timelines. This milestone enables us to accelerate our expected topline data readout to year-end 2026 and continue advancing KT-621 as a potential oral treatment option for patients living with atopic dermatitis and other Type 2 inflammatory diseases. Read more in our press release:

Kymera Therapeutics

19,878 görüntüleme • 7 gün önce

Breakthrough Update: Today, Vertex announced that they are beginning their Phase 3, or pivotal trial for VX-880, a stem cell-derived islet therapy. A pivotal trial gathers the data required for an FDA submission. This therapy is for people with type 1 diabetes (T1D) and hypoglycemia unawareness and severe hypoglycemic episodes. This is a HUGE first for the #T1D community as it is the first time a scalable cure for some people with T1D is entering this phase. Breakthrough T1D and the T1D Fund are incredibly proud to have supported this work in cell therapies—a top priority for our organization. We want to congratulate our partners at Vertex and thank all the patients who have participated in clinical trials. Your courage and commitment are inspiring. Learn more here:
1:29

Breakthrough Update: Today, Vertex announced that they are beginning their Phase 3, or pivotal trial for VX-880, a stem cell-derived islet therapy. A pivotal trial gathers the data required for an FDA submission. This therapy is for people with type 1 diabetes (T1D) and hypoglycemia unawareness and severe hypoglycemic episodes. This is a HUGE first for the #T1D community as it is the first time a scalable cure for some people with T1D is entering this phase. Breakthrough T1D and the T1D Fund are incredibly proud to have supported this work in cell therapies—a top priority for our organization. We want to congratulate our partners at Vertex and thank all the patients who have participated in clinical trials. Your courage and commitment are inspiring. Learn more here:

Breakthrough T1D

42,413 görüntüleme • 1 yıl önce

AI DISCOVERS REVOLUTIONARY NEW WAY TO REVERSE LUNG DAMAGE An AI system didn’t just design a new drug for pulmonary fibrosis; it first figured out which protein was causing the damage (TNIK), then designed a molecule to shut it down. In a 12-week trial, patients on the highest dose gained almost 100 ml of lung capacity, something that's never been achieved before with any other drug. For a disease that usually only gets worse, that’s like hitting rewind on the damage. Source: Nature Medicine
1:49

AI DISCOVERS REVOLUTIONARY NEW WAY TO REVERSE LUNG DAMAGE An AI system didn’t just design a new drug for pulmonary fibrosis; it first figured out which protein was causing the damage (TNIK), then designed a molecule to shut it down. In a 12-week trial, patients on the highest dose gained almost 100 ml of lung capacity, something that's never been achieved before with any other drug. For a disease that usually only gets worse, that’s like hitting rewind on the damage. Source: Nature Medicine

Mario Nawfal

29,345 görüntüleme • 9 ay önce

We’re excited to announce positive results from our BroADen Phase 1b clinical trial of KT-621, our investigational, first-in-class, oral STAT6 degrader, in patients with moderate to severe atopic dermatitis. The data provide a powerful validation of our industry-leading STAT6 degrader program and help accelerate our goal to deliver novel oral medicines to millions of patients around the world. Our deepest thanks to the patients, investigators, and the incredible Kymera team whose dedication made this significant milestone possible. Read more about the promising KT-621 data in our press release and join our live video webcast at 8:00AM ET today: #RevolutionizingImmunology
2:02

We’re excited to announce positive results from our BroADen Phase 1b clinical trial of KT-621, our investigational, first-in-class, oral STAT6 degrader, in patients with moderate to severe atopic dermatitis. The data provide a powerful validation of our industry-leading STAT6 degrader program and help accelerate our goal to deliver novel oral medicines to millions of patients around the world. Our deepest thanks to the patients, investigators, and the incredible Kymera team whose dedication made this significant milestone possible. Read more about the promising KT-621 data in our press release and join our live video webcast at 8:00AM ET today: #RevolutionizingImmunology

Kymera Therapeutics

15,338 görüntüleme • 6 ay önce

I met with a constituent who was participating in a cancer treatment trial that DOGE deemed unnecessary. I was proud to help advocate for Richard so he could resume his treatment. Cancer patients are not waste, fraud, and abuse. They're our loved ones who deserve care.
0:55

I met with a constituent who was participating in a cancer treatment trial that DOGE deemed unnecessary. I was proud to help advocate for Richard so he could resume his treatment. Cancer patients are not waste, fraud, and abuse. They're our loved ones who deserve care.

Senator Reverend Raphael Warnock

197,898 görüntüleme • 9 ay önce

Today we announced the initiation of a pivotal Phase 2b/3 trial for the treatment of patients with neovascular age-related macular degeneration (#wetAMD). Learn more: #ophthalmology
0:22

Today we announced the initiation of a pivotal Phase 2b/3 trial for the treatment of patients with neovascular age-related macular degeneration (#wetAMD). Learn more: #ophthalmology

Merck

16,948 görüntüleme • 3 ay önce

Our latest video in our partnership with Dr. Glaucomflecken summarizes a trial evaluating the clinical efficacy of tecovirimat against human clade II mpox. Read the full study for free:
1:23

Our latest video in our partnership with Dr. Glaucomflecken summarizes a trial evaluating the clinical efficacy of tecovirimat against human clade II mpox. Read the full study for free:

NEJM

37,322 görüntüleme • 2 ay önce

As Jonny Wilkinson predicted, it was a brilliant night Lymm RFC 🙌 A huge thank you to everyone who came to learn more about the Rugby Football Union Injured Players Foundation (IPF) & special thanks to our IPF Patron Sir Bill Beaumont and Ambassadors Jason Robinson Nick Mullins for sharing their stories 🏉 Amazing to hear from two England Rugby & British & Irish Lions legends. We can’t wait for the summer tours to kick off! 🌹 🦁 Read more ➡️ #rugbyfamily Cheshire RFU Lancashire RFU
3:16

As Jonny Wilkinson predicted, it was a brilliant night Lymm RFC 🙌 A huge thank you to everyone who came to learn more about the Rugby Football Union Injured Players Foundation (IPF) & special thanks to our IPF Patron Sir Bill Beaumont and Ambassadors Jason Robinson Nick Mullins for sharing their stories 🏉 Amazing to hear from two England Rugby & British & Irish Lions legends. We can’t wait for the summer tours to kick off! 🌹 🦁 Read more ➡️ #rugbyfamily Cheshire RFU Lancashire RFU

RFUIPF

28,038 görüntüleme • 1 yıl önce

🚀 How Recursion used AI to identify a novel approach for potentially treating the rare disease Familial Adenomatous Polyposis (FAP). A new video shares the story of Recursion’s investigational drug REC-4881 for the rare disease FAP which affects more than 50,000 people in the US and EU5 and has no approved medicines. Patients with this disease develop hundreds to thousands of polyps in their early teens to 20s that, if left untreated, have a nearly 100% risk of developing into colon cancer. ⬇️ Here’s how we did it: ▪️ Using the Recursion OS platform to analyze cell morphology, we tested thousands of compounds to find drugs that restored FAP-diseased cells to a healthy state. ▪️ This led us to REC-4881 — a drug that blocks a biological pathway called MEK1/2 – a new approach for treating FAP that had not been investigated clinically before. ▪️ Now, we’re using the full Recursion OS 2.0 platform — including our ClinTech real-world evidence – to fully understand disease burden and guide our clinical strategy, allowing us to expand patient eligibility for our trial. 💡 The takeaway: This program is the first clinical validation of the Recursion OS, and demonstrates our ability to translate unbiased phenotypic insights into potentially differentiated treatments for diseases with high unmet need. 👉 Read the full summary data in our December 8, 2025 press release here:
2:23

🚀 How Recursion used AI to identify a novel approach for potentially treating the rare disease Familial Adenomatous Polyposis (FAP). A new video shares the story of Recursion’s investigational drug REC-4881 for the rare disease FAP which affects more than 50,000 people in the US and EU5 and has no approved medicines. Patients with this disease develop hundreds to thousands of polyps in their early teens to 20s that, if left untreated, have a nearly 100% risk of developing into colon cancer. ⬇️ Here’s how we did it: ▪️ Using the Recursion OS platform to analyze cell morphology, we tested thousands of compounds to find drugs that restored FAP-diseased cells to a healthy state. ▪️ This led us to REC-4881 — a drug that blocks a biological pathway called MEK1/2 – a new approach for treating FAP that had not been investigated clinically before. ▪️ Now, we’re using the full Recursion OS 2.0 platform — including our ClinTech real-world evidence – to fully understand disease burden and guide our clinical strategy, allowing us to expand patient eligibility for our trial. 💡 The takeaway: This program is the first clinical validation of the Recursion OS, and demonstrates our ability to translate unbiased phenotypic insights into potentially differentiated treatments for diseases with high unmet need. 👉 Read the full summary data in our December 8, 2025 press release here:

Recursion

11,527 görüntüleme • 4 ay önce

In a message recorded for Stand Up To Cancer, The King spoke of the deep comfort found in compassion, expertise and kindness at every stage of treatment. To all those who care for patients and families and to everyone who offers support in ways seen and unseen - we thank you. #WorldCancerDay
0:41

In a message recorded for Stand Up To Cancer, The King spoke of the deep comfort found in compassion, expertise and kindness at every stage of treatment. To all those who care for patients and families and to everyone who offers support in ways seen and unseen - we thank you. #WorldCancerDay

The Royal Family

207,377 görüntüleme • 4 ay önce

We are the first hospital in Europe to deliver a new non-invasive cancer treatment to a patient outside of a clinical trial, after being fast-tracked by Department of Health and Social Care. This has been made possible by funding from a generous donation to Cambridge University from LiKaShing Foundation and Addenbrooke's Charity.
0:51

We are the first hospital in Europe to deliver a new non-invasive cancer treatment to a patient outside of a clinical trial, after being fast-tracked by Department of Health and Social Care. This has been made possible by funding from a generous donation to Cambridge University from LiKaShing Foundation and Addenbrooke's Charity.

Cambridge University Hospitals NHS

25,380 görüntüleme • 8 ay önce

Lung disease has many causes—from smoking and air pollution to infections and genetic factors. Our consultant physician shares key symptoms to watch for and the importance of timely care. For check-ups, diagnosis, or treatment call us on +256 41 425 9186.
2:22

Lung disease has many causes—from smoking and air pollution to infections and genetic factors. Our consultant physician shares key symptoms to watch for and the importance of timely care. For check-ups, diagnosis, or treatment call us on +256 41 425 9186.

Aga Khan University Hospital, Kampala

119,833 görüntüleme • 9 ay önce

The renovated Doak Campbell Stadium, new Dunlap Football Center and IPF combine to provide an unmatched experience for players, coaches and fans #NoleFamily | #KeepCLIMBing
3:56

The renovated Doak Campbell Stadium, new Dunlap Football Center and IPF combine to provide an unmatched experience for players, coaches and fans #NoleFamily | #KeepCLIMBing

FSU Football

387,673 görüntüleme • 10 ay önce

In the latest video in our partnership with Dr. Glaucomflecken, the REGENCY trial investigating the efficacy and safety of obinutuzumab when added to standard therapy in patients with active proliferative lupus nephritis is explained. Access the article for free:
1:46

In the latest video in our partnership with Dr. Glaucomflecken, the REGENCY trial investigating the efficacy and safety of obinutuzumab when added to standard therapy in patients with active proliferative lupus nephritis is explained. Access the article for free:

NEJM

144,755 görüntüleme • 1 yıl önce

We thank Baroness Wheeler for raising an important point in the #HouseOfLords today. Stroke nurses are vital for the care and treatment of stroke survivors and patients. But there is a shortage, and that shortage needs to be addressed.
1:19

We thank Baroness Wheeler for raising an important point in the #HouseOfLords today. Stroke nurses are vital for the care and treatment of stroke survivors and patients. But there is a shortage, and that shortage needs to be addressed.

Stroke Association

11,854 görüntüleme • 3 yıl önce

Our latest video in our partnership with Dr. Glaucomflecken summarizes a trial assessing the efficacy and safety of intravenous tenecteplase for acute central retinal artery occlusion. Read the full study for free:
1:17

Our latest video in our partnership with Dr. Glaucomflecken summarizes a trial assessing the efficacy and safety of intravenous tenecteplase for acute central retinal artery occlusion. Read the full study for free:

NEJM

33,682 görüntüleme • 2 ay önce

🔹 AI drug discovery, validated. Recursion recently announced the first clinical validation of its AI-enabled drug discovery platform – positive Phase 1b/2 data for the ongoing TUPELO study evaluating its AI-identified drug, REC-4881, in Familial Adenomatous Polyposis (FAP). This progressive rare disease affects more than 50,000 people in the U.S. and EU and has no FDA-approved treatments. It results in hundreds to thousands of polyps developing in the colon, and requires a lifetime of invasive surveillance and surgery. Recursion used AI not only to deliver the first potential treatment for this disease but also to quantify – for the first time at scale – the true natural progression of polyp burden in the trial-relevant population. It demonstrates the incredible breakthroughs that can come from merging proprietary data and AI – and the tangible impact on patient lives. 👉 See the full study results here:
1:29

🔹 AI drug discovery, validated. Recursion recently announced the first clinical validation of its AI-enabled drug discovery platform – positive Phase 1b/2 data for the ongoing TUPELO study evaluating its AI-identified drug, REC-4881, in Familial Adenomatous Polyposis (FAP). This progressive rare disease affects more than 50,000 people in the U.S. and EU and has no FDA-approved treatments. It results in hundreds to thousands of polyps developing in the colon, and requires a lifetime of invasive surveillance and surgery. Recursion used AI not only to deliver the first potential treatment for this disease but also to quantify – for the first time at scale – the true natural progression of polyp burden in the trial-relevant population. It demonstrates the incredible breakthroughs that can come from merging proprietary data and AI – and the tangible impact on patient lives. 👉 See the full study results here:

Recursion

255,879 görüntüleme • 6 ay önce

A new FDA-approved obesity pill could offer a lower-cost alternative to injectable GLP-1 drugs like Ozempic and Mounjaro, Jonathan LaPook, M.D reports. In a major clinical trial, people taking the highest dose lost about 11% of their body weight over 72 weeks. Eli Lilly says the oral medication will cost between $149 and $349 a month for people without insurance, with lower prices for some Medicare and Medicaid patients.
1:55

A new FDA-approved obesity pill could offer a lower-cost alternative to injectable GLP-1 drugs like Ozempic and Mounjaro, Jonathan LaPook, M.D reports. In a major clinical trial, people taking the highest dose lost about 11% of their body weight over 72 weeks. Eli Lilly says the oral medication will cost between $149 and $349 a month for people without insurance, with lower prices for some Medicare and Medicaid patients.

CBS News

19,903 görüntüleme • 3 ay önce

Today, we take the next step in Verve’s journey: the acquisition by Eli Lilly and Company is now complete. From the founding of Verve in 2018 to this milestone in 2025, we have worked with urgency and conviction to advance a bold idea — that a single-course gene editing medicine could one day offer durable protection from atherosclerotic cardiovascular disease. Lilly shares our vision of changing the treatment paradigm for cardiovascular disease. We believe Verve + Lilly is a uniquely powerful combination — one that brings together complementary strengths to deliver on the promise of single-course gene editing medicines for millions around the world. To the Verve team: thank you. Your drive, grit, and heart made this possible. And to the investigators and patients who have participated in our trials — we are deeply grateful. $VERV $LLY
2:24

Today, we take the next step in Verve’s journey: the acquisition by Eli Lilly and Company is now complete. From the founding of Verve in 2018 to this milestone in 2025, we have worked with urgency and conviction to advance a bold idea — that a single-course gene editing medicine could one day offer durable protection from atherosclerotic cardiovascular disease. Lilly shares our vision of changing the treatment paradigm for cardiovascular disease. We believe Verve + Lilly is a uniquely powerful combination — one that brings together complementary strengths to deliver on the promise of single-course gene editing medicines for millions around the world. To the Verve team: thank you. Your drive, grit, and heart made this possible. And to the investigators and patients who have participated in our trials — we are deeply grateful. $VERV $LLY

Sek Kathiresan MD

30,179 görüntüleme • 11 ay önce

Today marks a significant moment for Pfizer Inc. with the completion of our acquisition of Liate COHEN. Their highly differentiated candidates for obesity and cardiometabolic disease combined with Pfizer as a powerhouse in primary care, commercialization and manufacturing position us to reshape the treatment landscape. We’re not just participating in the obesity category. We aim to define it. Look forward to welcoming our new expert colleagues.
0:20

Today marks a significant moment for Pfizer Inc. with the completion of our acquisition of Liate COHEN. Their highly differentiated candidates for obesity and cardiometabolic disease combined with Pfizer as a powerhouse in primary care, commercialization and manufacturing position us to reshape the treatment landscape. We’re not just participating in the obesity category. We aim to define it. Look forward to welcoming our new expert colleagues.

Albert Bourla

18,652 görüntüleme • 7 ay önce